These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26418751)

  • 1. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.
    Delaney JR; Patel C; McCabe KE; Lu D; Davis MA; Tancioni I; von Schalscha T; Bartakova A; Haft C; Schlaepfer DD; Stupack DG
    Oncotarget; 2015 Oct; 6(31):31104-18. PubMed ID: 26418751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H; Shi C; Yan Z; Li H
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
    Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch signaling in serous ovarian cancer.
    Groeneweg JW; Foster R; Growdon WB; Verheijen RH; Rueda BR
    J Ovarian Res; 2014 Nov; 7():95. PubMed ID: 25366565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.
    Young AN; Herrera D; Huntsman AC; Korkmaz MA; Lantvit DD; Mazumder S; Kolli S; Coss CC; King S; Wang H; Swanson SM; Kinghorn AD; Zhang X; Phelps MA; Aldrich LN; Fuchs JR; Burdette JE
    Mol Cancer Ther; 2018 Oct; 17(10):2123-2135. PubMed ID: 30018048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.
    Stronach EA; Cunnea P; Turner C; Guney T; Aiyappa R; Jeyapalan S; de Sousa CH; Browne A; Magdy N; Studd JB; Sriraksa R; Gabra H; El-Bahrawy M
    Oncotarget; 2015 Oct; 6(31):31593-603. PubMed ID: 26267317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.
    Sun ZL; Dong JL; Wu J
    Biomed Pharmacother; 2017 Jan; 85():303-312. PubMed ID: 27899257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
    Liu N; Tai S; Ding B; Thor RK; Bhuta S; Sun Y; Huang J
    Endocr Relat Cancer; 2012 Oct; 19(5):711-23. PubMed ID: 22919067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression.
    Persenaire C; Babbs B; Yamamoto TM; Nebbia M; Jordan KR; Adams S; Lambert JR; Bitler BG
    Mol Carcinog; 2024 Jul; 63(7):1248-1259. PubMed ID: 38558423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
    Mei L; Chen Y; Wang Z; Wang J; Wan J; Yu C; Liu X; Li W
    Br J Pharmacol; 2015 May; 172(9):2232-45. PubMed ID: 25521075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKIIγ/AKT-mediated pathway.
    Jing Z; Sui X; Yao J; Xie J; Jiang L; Zhou Y; Pan H; Han W
    Cancer Lett; 2016 Mar; 372(2):226-38. PubMed ID: 26803057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
    Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
    Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
    Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway.
    Pang Y; Si M; Sun B; Niu L; Xu X; Lu T; Yuan H; Lou H
    Food Chem Toxicol; 2014 Jul; 69():163-74. PubMed ID: 24751974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy as an emerging therapy target for ovarian carcinoma.
    Zhan L; Zhang Y; Wang W; Song E; Fan Y; Li J; Wei B
    Oncotarget; 2016 Dec; 7(50):83476-83487. PubMed ID: 27825125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.